Recurrent Prostate Cancer Clinical Trial
Official title:
Stereotactic Body Radiation Therapy to the Prostate Fossa: Phase I Dose Escalation Study
Verified date | March 2024 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with prostate cancer after undergoing surgery. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
Status | Active, not recruiting |
Enrollment | 26 |
Est. completion date | June 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: - History of diagnosis of prostate cancer after undergoing prostatectomy - No evidence of regional nodal or distant metastases based on computed tomography (CT) abdomen and pelvis and whole body bone scan within 120 days prior to study entry; nodes less than 1.5 cm will be considered reactive and biopsy is not required; nodes 1.5 cm or larger are required to undergo biopsy and be negative prior to study registration; bone scan findings in the absence of blastic or lytic lesion correlates on CT imaging will also be deemed non-neoplastic - Eastern Cooperative Oncology Group (ECOG) performance scale 0-2 - Child bearing potential: In this patient population, this pertains to the ability to conceive a child; eligible patients already have received prostatectomy, and therefore this risk is not applicable - Prostate specific antigen (PSA) value can be undetectable up to a value of 2.0 within 30 days prior to study entry - PSA value that is undetectable can be enrolled if pathology from prostatectomy demonstrates one or more of the following: positive margin, extracapsular extension, or seminal vesicle invasion - All subjects must have the ability to understand and the willingness to sign a written informed consent Exclusion Criteria: - Patients should not have any uncontrolled illness including ongoing or active infection - Patients may not be receiving any other investigational agents, or concurrent biological chemotherapy - Patients with history of prior malignancies (with exception to non-melanoma skin cancer) are ineligible for this study, unless they are documented to be disease-free for at least 5 years - Study-specific exclusions: - History of prior radiation to the pelvis - History of uncontrolled inflammatory bowel disease - Unable to comply with radiation therapy procedures - Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study |
Country | Name | City | State |
---|---|---|---|
United States | City of Hope Medical Center | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MTD, defined as the highest dose tested in which fewer than 33% of patients experienced dose limiting toxicity, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 | Tables will be created to summarize these toxicities and side effects by dose level. | 90 days | |
Secondary | Incidence of acute toxicities observed at each dose level graded according to the NCI CTCAE version 4.0 | Tables will be created to summarize these toxicities and side effects by dose level. | Up to 90 days | |
Secondary | Incidence of late toxicities observed at each dose level graded according to the NCI CTCAE version 4.0 | Tables will be created to summarize these toxicities and side effects by dose level. | Up to 3 years | |
Secondary | Biochemical progression-free survival | Estimated using Kaplan-Meier. 95% confidence intervals should be provided. | Up to 3 years | |
Secondary | Prospective quality-of-life data related to bowel, urinary, and sexual health using the numerical scores generated from the patient questionnaires | Quality of life questionnaires include the International Prostate Symptom Scale (IPSS), sexual health inventory for men (SHIM), and Merrick rectal function scale. | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02217709 -
Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT03718260 -
PSMA-PET Registry for Recurrent Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT01685125 -
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT01054079 -
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
|
Phase 2 | |
Terminated |
NCT00512668 -
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
|
Phase 1 | |
Completed |
NCT00103194 -
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT00087139 -
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05304858 -
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
|
||
Completed |
NCT02250014 -
The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer
|
Phase 1 | |
Active, not recruiting |
NCT01655836 -
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
|
Phase 1 | |
Terminated |
NCT01866423 -
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06070272 -
Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
|
||
Completed |
NCT01468532 -
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01260688 -
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
|
Phase 2 | |
Completed |
NCT01682941 -
Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen
|
N/A | |
Completed |
NCT01220817 -
Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study
|
Phase 2 | |
Completed |
NCT00775866 -
MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy
|
N/A | |
Completed |
NCT00074022 -
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05044754 -
SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy
|
||
Completed |
NCT01808222 -
FACBC for Recurrent Prostate Cancer
|
Phase 2 |